search
Back to results

MDMA-Assisted CBCT for PTSD vs CBCT RCT

Primary Purpose

Post Traumatic Stress Disorder

Status
Not yet recruiting
Phase
Phase 2
Locations
Canada
Study Type
Interventional
Intervention
MDMA assisted psychotherapy
Psychotherapy
Sponsored by
Remedy
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Post Traumatic Stress Disorder focused on measuring MDMA, Cognitive Behavioural Conjoint Therapy (CBCT), Relationship functioning

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria Participant with PTSD Participant with PTSD Meet criteria for PTSD Have a close other person who is able and willing to participate in this study Are at least 18 years old Are a resident of Ontario and live within the Greater Toronto Area (GTA) Are in good physical health Are proficient in speaking and reading English Are willing to have all visits audio and video recorded Are able to swallow pills Agree to all study rules and commit to all medical and therapy visits If in psychotherapy, are willing to allow the study therapists to communicate directly with your therapist Are willing to stop taking psychiatric medications, herbal supplements, prescription and nonprescription medications during the study Agree to stay overnight on two separate occasions after each full-day MDMA-Assisted Therapy Session, and not to drive for at least 24 hours after taking MDMA Are not pregnant and will commit to not becoming pregnant during the study, if you are able to become pregnant Have a supportive relative, spouse, close friend or other caregiver not participating in this study who can serve as your emergency contact Agree to inform the researchers within 48 hours of any medical conditions and procedures Agree to not participate in any other clinical trials during this study Close Significant Other Have a close other person who meets criteria for PTSD and is able and willing to participate in this study Are at least 18 years old Are a resident of Ontario and live within the Greater Toronto Area (GTA) Are in good physical health Are proficient in speaking and reading English Are willing to have all visits audio and video recorded Are able to swallow pills Agree to all study rules and commit to all medical and therapy visits If in psychotherapy, are willing to allow the study therapists to communicate directly with your therapist Are willing to stop taking psychiatric medications, herbal supplements, prescription and nonprescription medications during the study Agree to stay overnight on two separate occasions after each full-day MDMA-Assisted Therapy Session, and not to drive for at least 24 hours after taking MDMA Are not pregnant and will commit to not becoming pregnant during the study, if you are able to become pregnant Have a supportive relative, spouse, close friend or other caregiver not participating in this study who can serve as your emergency contact Agree to inform the researchers within 48 hours of any medical conditions and procedure Agree to not participate in any other clinical trials during this study Exclusion Criteria Participant with PTSD Are pregnant or could become pregnant and not using birth control Have a history of, or a current psychotic disorder or bipolar 1 disorder or dissociative identity disorder Have a history of a medical condition that could make receiving MDMA unsafe (e.g. glaucoma, heart attack, stroke, aneurysm) Have a history of Diabetes Mellitus (Type 2) that a doctor determines is not stable Have hypothyroidism (low activity in the thyroid gland) and are not on thyroid replacement Have high blood pressure, a history of heart disease, heart failure, irregular activity in the heart or require heart medication Have liver disease with symptoms Have history of hyponatremia (when you have decreased levels of sodium in the blood, which can cause confusion, seizures, fatigue and low levels of consciousness) Have history of hyperthermia (when you have a dangerously overheated body, usually in response to hot, humid weather) Weigh less than 48 kg Have recently engaged in suicidal behaviour or had serious suicidal thoughts (this will be assessed by the study team) Require ongoing therapy with a psychiatric medication Have a current eating disorder with active purging Have current major depressive disorder with psychotic features Are a serious risk to others Have recently received Electroconvulsive Therapy (ECT) Have recently engaged in ketamine-assisted therapy or used ketamine Have current substance use disorder with physiological dependence (not including caffeine or nicotine) Have recently used "Ecstasy" (material represented as containing MDMA) Are not able to give adequate informed consent Are not able to adhere to the requirements for procedures, attendance and timing of visits, and observe limits regarding study staff time and support as indicated by a time-limited clinical trial Are currently engaged in compensation litigation whereby financial gain would be achieved from prolonged symptoms of PTSD or any other psychiatric disorders Close Significant Other Meet criteria for PTSD Are pregnant or could become pregnant and not using birth control Have a history of, or a current psychotic disorder or bipolar 1 disorder or dissociative identity disorder Have a history of a medical condition that could make receiving MDMA unsafe (e.g. glaucoma, heart attack, stroke, aneurysm) Have a history of Diabetes Mellitus (Type 2) that a doctor determines is not stable Have hypothyroidism (low activity in the thyroid gland) and are not on thyroid replacement Have high blood pressure, a history of heart disease, heart failure, irregular activity in the heart or require heart medication Have liver disease with symptoms Have history of hyponatremia (when you have decreased levels of sodium in the blood, which can cause confusion, seizures, fatigue and low levels of consciousness) Have history of hyperthermia (when you have a dangerously overheated body, usually in response to hot, humid weather) Weigh less than 48 kg Have recently engaged in suicidal behaviour or had serious suicidal thoughts (this will be assessed by the study team) Require ongoing therapy with a psychiatric medication Have a current eating disorder with active purging Have current major depressive disorder with psychotic features Are a serious risk to others Have recently received Electroconvulsive Therapy (ECT) Have recently engaged in ketamine-assisted therapy or used ketamine Have current substance use disorder with physiological dependence (not including caffeine or nicotine) Have recently used "Ecstasy" (material represented as containing MDMA) Are not able to give adequate informed consent Are not able to adhere to the requirements for procedures, attendance and timing of visits, and observe limits regarding study staff time and support as indicated by a time-limited clinical trial Are currently engaged in compensation litigation whereby financial gain would be achieved from prolonged symptoms of PTSD or any other psychiatric disorders

Sites / Locations

  • Remedy Institute

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

MDMA-Assisted CBCT Condition

CBCT-Only Condition

Arm Description

Dyads will undergo a 7-week course of CBCT psychotherapy for PTSD with two sessions that integrate MDMA-assisted psychotherapy. MDMA will be administered in two separate sessions and integrated into the psychotherapy protocol. The two doses of MDMA during this study will be used as an adjunct to psychotherapy.

Dyads will undergo a 7-week course of CBCT psychotherapy for PTSD. Dyads who have undergone the CBCT-Only condition will have the option to do a crossover and have the two MDMA sessions after follow-up.

Outcomes

Primary Outcome Measures

Feasibility of Intervention Measure (FIM)
The Feasibility of Intervention Measure (FIM) is a self-report questionnaire in which respondents indicate the extent to which they believe that the treatment can be delivered in a given setting. Respondents indicate their responses on a five-point Likert-type (1=completely disagree, 5= completely agree).
Safety of Intervention
Safety will be assessed by examining the frequency and severity of adverse events (AEs), serious AEs (SAEs), treatment emergent AES (TEAEs), and AEs of special interest. Participants are asked to report any AEs, SAEs, TEAEs, and AEs of special interest as they happen and during any communication with the therapist or independent assessor.
Intervention Appropriateness Measures (IAM)
Intervention Appropriateness Measures (IAM) is a self-report measure of the perceived fit, relevance, or compatibility of an intervention. Respondents record their answers on a five-point Likert-type scale (1=completely disagree, 5= completely agree).
Long Term Follow-Up Questionnaire (LTFUQ)
The Long Term Follow-Up Questionnaire (LTFUQ) is a self-report measure that assesses the long-term benefits and harms of MDMA-assisted therapy.
Clinician Administered PTSD Scale (CAPS-5)
The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-5. It contains symptom subscales, a total severity score, and a diagnostic score. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.

Secondary Outcome Measures

Posttraumatic Stress Disorder Checklist for the DSM-5 (PCL-5)
PTSD Checklist for the DSM-5 (PCL-5) is a self-report questionnaire in which respondents indicate the presence and severity of PTSD symptoms, derived from the DSM-5 symptoms of PTSD. Participants indicate how much distress they have experienced due to symptoms on a five-point Likert-type scale (1 = not at all, 5 = extremely). The total PCL-5 score (a sum of all 20 items) provides an index of overall PTSD symptom severity with higher scores indicating higher severity.
Quality of Relationships Inventory (QRI)
The Quality of Relationships Inventory (QRI) is a self-report questionnaire that uses the role of situational, intrapersonal, and interpersonal in social support processes to assess supportive and conflictual aspects of close non-intimate relationships.
Couple Satisfaction Index (CSI)
The Couple Satisfaction Index (CSI) is a self-report questionnaire that measures intimate relationship functioning. Respondents answer most of the questions on a six-point Likert-type scale (0= never, 5= all the time) and one question on a seven-point Likert-type scale ( 0= extremely unhappy, 6= perfect).
Patient Health Questionnaire-9 (PHQ-9)
The Patient Health Questionnaire-9 (PHQ-9) is used to assess depressive symptom severity. The PHQ-9 includes items which correspond with the diagnostic criteria for DSM-IV major depressive disorder. Scores can indicate either no depression, minimal, mild, moderate, moderately severe, or severe depression. Higher scores indicate higher severity in depressive symptoms.

Full Information

First Posted
September 13, 2023
Last Updated
September 13, 2023
Sponsor
Remedy
Collaborators
Remedy Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT06044675
Brief Title
MDMA-Assisted CBCT for PTSD vs CBCT RCT
Official Title
A Randomized Trial of MDMA-Assisted Cognitive-Behavioural Conjoint Therapy (CBCT) Versus CBCT in Dyads in Which One Member Has Posttraumatic Stress Disorder (PTSD)
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
October 15, 2023 (Anticipated)
Primary Completion Date
December 31, 2025 (Anticipated)
Study Completion Date
October 15, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Remedy
Collaborators
Remedy Institute

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study aims to evaluate the safety, feasibility, acceptability, and effectiveness of MDMA-assisted Cognitive-Behavioral Conjoint Therapy (CBCT) versus CBCT alone for the treatment of Post-Traumatic Stress Disorder (PTSD). PTSD is a debilitating condition that significantly impacts interpersonal relationships and the functioning of individuals and their loved ones. There is also a well-established reciprocal relationship between interpersonal relationships, PTSD, and recovery. CBCT is a manualized treatment for PTSD that simultaneously addresses PTSD symptoms and relationship satisfaction. It provides dyads with behavioral tools to navigate PTSD-related challenges, as well as the knowledge behind PTSD and how it impacts relationships. Previous research has demonstrated the efficacy of CBCT in improving PTSD symptoms, partner functioning, and relationship satisfaction in both distressed and non-distressed dyads. MDMA is a drug commonly used recreationally that has been increasingly studied because of its ability to reduce the impact of PTSD symptoms. The effects of MDMA are reduced fear, enhanced communication, trust and introspection, and increased empathy and compassion. The effects of MDMA create a state that enhances the positive effects of therapy by increasing the ability to tolerate negative emotions and allowing clients to stay engaged in therapy without being overwhelmed by the intense emotions surrounding the memories of traumatic events. It is believed that MDMA may help promote the effects of CBCT due to its ability to induce empathy and interpersonal openness. This randomized study is the second study designed to explore the efficacy of combining MDMA-assisted therapy with CBCT. This study will enroll 30 dyads, where one individual has symptoms of PTSD. Participants will undergo a 7-week psychotherapy course, in MDMA-assisted CBCT or CBCT alone. In the MDMA-assisted CBCT, participants will go through CBCT sessions, and two doses of MDMA will be used as an adjunct to psychotherapy. Participants assigned to the CBCT-only condition will go through CBCT sessions and will have the opportunity to crossover and receive the two MDMA sessions after follow-up. The primary goal of this research is to contribute to the literature on MDMA-assisted CBCT by investigating its feasibility, safety, acceptability, and effectiveness, and by comparing it to active PTSD treatments.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Post Traumatic Stress Disorder
Keywords
MDMA, Cognitive Behavioural Conjoint Therapy (CBCT), Relationship functioning

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
MDMA-Assisted CBCT Condition
Arm Type
Experimental
Arm Description
Dyads will undergo a 7-week course of CBCT psychotherapy for PTSD with two sessions that integrate MDMA-assisted psychotherapy. MDMA will be administered in two separate sessions and integrated into the psychotherapy protocol. The two doses of MDMA during this study will be used as an adjunct to psychotherapy.
Arm Title
CBCT-Only Condition
Arm Type
Active Comparator
Arm Description
Dyads will undergo a 7-week course of CBCT psychotherapy for PTSD. Dyads who have undergone the CBCT-Only condition will have the option to do a crossover and have the two MDMA sessions after follow-up.
Intervention Type
Drug
Intervention Name(s)
MDMA assisted psychotherapy
Other Intervention Name(s)
MDMA-assisted CBCT
Intervention Description
This treatment combines MDMA with a well researched treatment for PTSD for dyads known as CBCT. Dyads will undergo a 7-week course of psychotherapy with two doses of MDMA will be used as an adjunct to psychotherapy.
Intervention Type
Behavioral
Intervention Name(s)
Psychotherapy
Other Intervention Name(s)
CBCT
Intervention Description
A manualized treatment for PTSD for dyads wherein one person has symptoms of PTSD. This intervention is 7-week course of psychotherapy that is designed to simultaneously improve PTSD symptoms and relationship functioning through education and skill training.
Primary Outcome Measure Information:
Title
Feasibility of Intervention Measure (FIM)
Description
The Feasibility of Intervention Measure (FIM) is a self-report questionnaire in which respondents indicate the extent to which they believe that the treatment can be delivered in a given setting. Respondents indicate their responses on a five-point Likert-type (1=completely disagree, 5= completely agree).
Time Frame
3-Month Follow-up
Title
Safety of Intervention
Description
Safety will be assessed by examining the frequency and severity of adverse events (AEs), serious AEs (SAEs), treatment emergent AES (TEAEs), and AEs of special interest. Participants are asked to report any AEs, SAEs, TEAEs, and AEs of special interest as they happen and during any communication with the therapist or independent assessor.
Time Frame
Baseline (enrolment) to Follow-up (3-month follow-up)
Title
Intervention Appropriateness Measures (IAM)
Description
Intervention Appropriateness Measures (IAM) is a self-report measure of the perceived fit, relevance, or compatibility of an intervention. Respondents record their answers on a five-point Likert-type scale (1=completely disagree, 5= completely agree).
Time Frame
3-month follow-up
Title
Long Term Follow-Up Questionnaire (LTFUQ)
Description
The Long Term Follow-Up Questionnaire (LTFUQ) is a self-report measure that assesses the long-term benefits and harms of MDMA-assisted therapy.
Time Frame
3-Month Follow-up
Title
Clinician Administered PTSD Scale (CAPS-5)
Description
The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-5. It contains symptom subscales, a total severity score, and a diagnostic score. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.
Time Frame
Baseline (enrolment) to Follow-up (3-month follow-up)
Secondary Outcome Measure Information:
Title
Posttraumatic Stress Disorder Checklist for the DSM-5 (PCL-5)
Description
PTSD Checklist for the DSM-5 (PCL-5) is a self-report questionnaire in which respondents indicate the presence and severity of PTSD symptoms, derived from the DSM-5 symptoms of PTSD. Participants indicate how much distress they have experienced due to symptoms on a five-point Likert-type scale (1 = not at all, 5 = extremely). The total PCL-5 score (a sum of all 20 items) provides an index of overall PTSD symptom severity with higher scores indicating higher severity.
Time Frame
Baseline (enrolment) to Follow-up (3-month follow-up)
Title
Quality of Relationships Inventory (QRI)
Description
The Quality of Relationships Inventory (QRI) is a self-report questionnaire that uses the role of situational, intrapersonal, and interpersonal in social support processes to assess supportive and conflictual aspects of close non-intimate relationships.
Time Frame
Baseline (enrolment) to Follow-up (3-month follow-up)
Title
Couple Satisfaction Index (CSI)
Description
The Couple Satisfaction Index (CSI) is a self-report questionnaire that measures intimate relationship functioning. Respondents answer most of the questions on a six-point Likert-type scale (0= never, 5= all the time) and one question on a seven-point Likert-type scale ( 0= extremely unhappy, 6= perfect).
Time Frame
Baseline (enrolment) to Follow-up (3-month follow-up)
Title
Patient Health Questionnaire-9 (PHQ-9)
Description
The Patient Health Questionnaire-9 (PHQ-9) is used to assess depressive symptom severity. The PHQ-9 includes items which correspond with the diagnostic criteria for DSM-IV major depressive disorder. Scores can indicate either no depression, minimal, mild, moderate, moderately severe, or severe depression. Higher scores indicate higher severity in depressive symptoms.
Time Frame
Baseline (enrolment) to Follow-up (3-month follow-up)
Other Pre-specified Outcome Measures:
Title
Posttraumatic Growth Inventory (PTGI)
Description
The Posttraumatic Growth Inventory (PTGI) is a 21-item self-report measure of perceived growth or benefits occurring after a traumatic event. It contains five subscales: relationship to others, new possibilities, personal strength, spiritual change, and appreciation of life.
Time Frame
Baseline (enrolment) to Follow-up (3 month follow-up)
Title
Self-Compassion Scale-Short Form (SCS-SF)
Description
The Self-Compassion Scale-Short Form (SCS-SF) is a 12-item self-report measures that assess self-compassion. This measure is comprised of the following subscales: self-kindness, self-judgement, common humanity, isolation, mindfulness, and over-identification. Respondents answer questions on a five-point Likert-type scale (1= almost never, 5= almost always).
Time Frame
Baseline (enrolment) to Follow-up (3-month follow-up)
Title
Brief Experiential Avoidance Questionnaire (BEAQ)
Description
The Brief Experiential Avoidance Questionnaire (BEAQ) is a 15-item self-report measure that assesses experiential avoidance. Respondents rate the extent to which they agree with each item on a six-point Likert-type scale (1 = strongly disagree, 6= strongly agree).
Time Frame
Baseline (enrolment) to Follow-up (3-month follow-up)
Title
Alcohol Use Disorders Identification Test (AUDIT), Cannabis Use Disorders Identification Test-Revised (CUDIT-R), and Drug Use Disorders Identification Test (DUDIT)
Description
The Alcohol Use Disorders Identification Test (AUDIT), Cannabis Use Disorders Identification Test-Revised (CUDIT-R), and Drug Use Disorders Identification Test (DUDIT) are self-report questionnaires that assess alcohol and substance use.
Time Frame
Baseline (enrolment) to Follow-up (3-month follow-up)
Title
Brief Posttraumatic Cognitions Inventory (PTCI-9)
Description
The Brief Posttraumatic Cognitions Inventory (PTCI-9) is a nine-item self-report questionnaire that measures appraisals related to trauma. Respondents answer the questionnaire on a seven-point Likert-type scale (1= totally disagree, 7= totally agree).
Time Frame
Baseline (enrolment) to Follow-up (3-month follow-up)
Title
MOS Social Support Survey (MOS-SSS)
Description
The MOS Social Support Survey (MOS-SSS) is a 20-item multidimensional self-report questionnaire that assess perceived availability of social support. Respondents answer questions on a seven-point Likert-type scale (1 = none of the time, 7= all of the time), where higher score indicate greater levels of available social support.
Time Frame
Baseline (enrolment) to Follow-up (3-month follow-up)
Title
Significant Others' Responses to Trauma Scale (SORTS)
Description
The Significant Others' Responses to Trauma Scale (SORTS) is a 14-item self-report questionnaire that measures relationship problems and the psychological distress of partners of people with PTSD. Respondents answer questions on a five-point Likert scale (0-4).
Time Frame
Baseline (enrolment) to Follow-up (3-month follow-up)
Title
Modified Experiences in Close Relationships (ECR-M16)
Description
The Modified Experiences in Close Relationships (ECR-M16) is a 16-item self-report questionnaire that assesses attachment style. Half of the items on the scale measure attachment anxiety and the other half measures attachment avoidance. Respondents answer questions on a seven-point Likert-type scale (1= disagree, 7=agree).
Time Frame
Baseline (enrolment) to Follow-up (3-month follow-up)
Title
Psychological Insights Questionnaire (PIQ)
Description
The Psychological Insights Questionnaire (PIQ) is a a 23-item self-report measure that assesses acute experiences of insight (i.e., beliefs, memories, emotions, etc.). Respondents answer questions on a six-point Likert-type scale (0= no, not at all; 5= extremely).
Time Frame
Baseline (enrolment) to Follow-up (3-month follow-up)
Title
Mystical Experiences Questionnaire (MEQ30)
Description
The Mystical Experiences Questionnaire (MEQ30) is a 30-item self-report questionnaire that assesses discrete mystical experiences. Respondents rate the extent to which the experience mystical feeling, positive mood, transcendence of space/time, and ineffability on a five-point Likert-type scale (0= no/not at all, 4= extreme).
Time Frame
Baseline (enrolment) to Follow-up (3-month follow-up)
Title
Columbia-Suicide Severity Rating Scale (C-SSRS)
Description
The Columbia-Suicide Severity Rating Scale (C-SSRS) is a clinician-administered measure of suicidal behaviour devised to detect potential suicidal thoughts or behaviours. It is designed to assess suicidal ideation, ideation intensity, and behaviour.
Time Frame
Baseline (enrolment) to Follow-up (3-month follow-up)
Title
Credibility Expectancy Questionnaire (CEQ)
Description
The Credibility Expectancy Questionnaire (CEQ) is a six-item self-report measure of beliefs about treatment credibility and expectancy of treatment outcomes. The some questions on the questionnaire are answered on a scale ranging from 1 (not at all) to 9 (very much) and that others are answered on a scale ranging from 0 (not at all) to 100% (very much).
Time Frame
Baseline (enrolment)
Title
Working Alliance Inventory-Observer Form (WAI-O)
Description
The Working Alliance Inventory-Observer Form (WAI-O) is a 36-item observer-rated measure of the alliance between a therapist and client. Observers rate each item on a scale from 1 (Never applies to the dyad) to 7 (Always applies to the dyad).
Time Frame
First therapy session, Mid-point, and Follow-up (3-month follow-up)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria Participant with PTSD Participant with PTSD Meet criteria for PTSD Have a close other person who is able and willing to participate in this study Are at least 18 years old Are a resident of Ontario and live within the Greater Toronto Area (GTA) Are in good physical health Are proficient in speaking and reading English Are willing to have all visits audio and video recorded Are able to swallow pills Agree to all study rules and commit to all medical and therapy visits If in psychotherapy, are willing to allow the study therapists to communicate directly with your therapist Are willing to stop taking psychiatric medications, herbal supplements, prescription and nonprescription medications during the study Agree to stay overnight on two separate occasions after each full-day MDMA-Assisted Therapy Session, and not to drive for at least 24 hours after taking MDMA Are not pregnant and will commit to not becoming pregnant during the study, if you are able to become pregnant Have a supportive relative, spouse, close friend or other caregiver not participating in this study who can serve as your emergency contact Agree to inform the researchers within 48 hours of any medical conditions and procedures Agree to not participate in any other clinical trials during this study Close Significant Other Have a close other person who meets criteria for PTSD and is able and willing to participate in this study Are at least 18 years old Are a resident of Ontario and live within the Greater Toronto Area (GTA) Are in good physical health Are proficient in speaking and reading English Are willing to have all visits audio and video recorded Are able to swallow pills Agree to all study rules and commit to all medical and therapy visits If in psychotherapy, are willing to allow the study therapists to communicate directly with your therapist Are willing to stop taking psychiatric medications, herbal supplements, prescription and nonprescription medications during the study Agree to stay overnight on two separate occasions after each full-day MDMA-Assisted Therapy Session, and not to drive for at least 24 hours after taking MDMA Are not pregnant and will commit to not becoming pregnant during the study, if you are able to become pregnant Have a supportive relative, spouse, close friend or other caregiver not participating in this study who can serve as your emergency contact Agree to inform the researchers within 48 hours of any medical conditions and procedure Agree to not participate in any other clinical trials during this study Exclusion Criteria Participant with PTSD Are pregnant or could become pregnant and not using birth control Have a history of, or a current psychotic disorder or bipolar 1 disorder or dissociative identity disorder Have a history of a medical condition that could make receiving MDMA unsafe (e.g. glaucoma, heart attack, stroke, aneurysm) Have a history of Diabetes Mellitus (Type 2) that a doctor determines is not stable Have hypothyroidism (low activity in the thyroid gland) and are not on thyroid replacement Have high blood pressure, a history of heart disease, heart failure, irregular activity in the heart or require heart medication Have liver disease with symptoms Have history of hyponatremia (when you have decreased levels of sodium in the blood, which can cause confusion, seizures, fatigue and low levels of consciousness) Have history of hyperthermia (when you have a dangerously overheated body, usually in response to hot, humid weather) Weigh less than 48 kg Have recently engaged in suicidal behaviour or had serious suicidal thoughts (this will be assessed by the study team) Require ongoing therapy with a psychiatric medication Have a current eating disorder with active purging Have current major depressive disorder with psychotic features Are a serious risk to others Have recently received Electroconvulsive Therapy (ECT) Have recently engaged in ketamine-assisted therapy or used ketamine Have current substance use disorder with physiological dependence (not including caffeine or nicotine) Have recently used "Ecstasy" (material represented as containing MDMA) Are not able to give adequate informed consent Are not able to adhere to the requirements for procedures, attendance and timing of visits, and observe limits regarding study staff time and support as indicated by a time-limited clinical trial Are currently engaged in compensation litigation whereby financial gain would be achieved from prolonged symptoms of PTSD or any other psychiatric disorders Close Significant Other Meet criteria for PTSD Are pregnant or could become pregnant and not using birth control Have a history of, or a current psychotic disorder or bipolar 1 disorder or dissociative identity disorder Have a history of a medical condition that could make receiving MDMA unsafe (e.g. glaucoma, heart attack, stroke, aneurysm) Have a history of Diabetes Mellitus (Type 2) that a doctor determines is not stable Have hypothyroidism (low activity in the thyroid gland) and are not on thyroid replacement Have high blood pressure, a history of heart disease, heart failure, irregular activity in the heart or require heart medication Have liver disease with symptoms Have history of hyponatremia (when you have decreased levels of sodium in the blood, which can cause confusion, seizures, fatigue and low levels of consciousness) Have history of hyperthermia (when you have a dangerously overheated body, usually in response to hot, humid weather) Weigh less than 48 kg Have recently engaged in suicidal behaviour or had serious suicidal thoughts (this will be assessed by the study team) Require ongoing therapy with a psychiatric medication Have a current eating disorder with active purging Have current major depressive disorder with psychotic features Are a serious risk to others Have recently received Electroconvulsive Therapy (ECT) Have recently engaged in ketamine-assisted therapy or used ketamine Have current substance use disorder with physiological dependence (not including caffeine or nicotine) Have recently used "Ecstasy" (material represented as containing MDMA) Are not able to give adequate informed consent Are not able to adhere to the requirements for procedures, attendance and timing of visits, and observe limits regarding study staff time and support as indicated by a time-limited clinical trial Are currently engaged in compensation litigation whereby financial gain would be achieved from prolonged symptoms of PTSD or any other psychiatric disorders
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Alexis Collins, BA
Phone
4372914747
Email
research@remedyinstitute.ca
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Paul Uy, MD
Organizational Affiliation
Remedy Institute
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Anne Wagner, PhD
Organizational Affiliation
Remedy Institute
Official's Role
Study Chair
Facility Information:
Facility Name
Remedy Institute
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M6G 1L5
Country
Canada
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alexis Collins, BA

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

MDMA-Assisted CBCT for PTSD vs CBCT RCT

We'll reach out to this number within 24 hrs